Let's see if we can try this from a different vantage point. Your focus is that the more people here project Elite's garnered revenue to be a higher figure the lower and lower the PPS ends up. Then you go on to discuss the API Phentermine supply issue.
I think you have a more solid argument that the API supply issue hurt Elite's PPs. In essence, you could argue that Elite's PPS is where it is at currently related to that supply issue. But then to move over to your other argument that the higher the projected revenue of Elite is the lower the PPS becomes. The problem with this line of reasoning is that the projected billion(s) dollar revenue is projected from Abuse Resistant Products that haven't even been launched yet.
In other words, the Abuse Resistant Opioid Market is in the Billions and when Tangerine says the ceiling is in the Billions. That statement is true. None of us know how much of the multi billion dollar market Elite could capture. What we know is that Purdue captured around 3.6 Billion off of one Oxycodone product. And how many Abuse Resistant Opioid products did Jerry say he wanted to market? A whole line. So if Jerry actually pulls that off....I would say Elite could actually capture a nice chunk of the multi billion dollar market.
Market Data 
Markets 
AI
